Literature DB >> 11557172

Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent.

M J Millan1, M Brocco, A Gobert, G Dorey, P Casara, A Dekeyne.   

Abstract

The selective, non-peptidergic corticotropin-releasing factor (CRF)(1) receptor antagonists, CP154,526 and DMP695, dose-dependently increased punished responses of rats in a Vogel conflict test and enhanced social interaction (SI) of rats in an unfamiliar environment. They were, however, inactive in a plus-maze procedure and failed to reduce ultrasonic vocalizations (USV) associated with an aversive environment. In contrast, the benzodiazepine, chlordiazepoxide, was effective in all these procedures. Further, the serotonin (5-HT)(1A) agonist, flesinoxan, was active in each paradigm (except the plus-maze) while the 5-HT(2C) antagonist, SB242,084, was effective in the SI and Vogel but not the plus-maze and USV procedures. In contrast to chlordiazepoxide, flesinoxan and SB242,084, CP154,526 did not modify dialysate levels of 5-HT, norepinephrine (NE) and dopamine (DA) in the frontal cortex (FCX) of freely moving rats. In conclusion, CP154,526 and DMP695 possess a common and distinctive profile of anxiolytic action expressed in the absence of an intrinsic influence upon monoamine release.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557172     DOI: 10.1016/S0893-133X(01)00244-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  15 in total

Review 1.  Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.

Authors:  Eric P Zorrilla; Markus Heilig; Harriet de Wit; Yavin Shaham
Journal:  Drug Alcohol Depend       Date:  2013-01-05       Impact factor: 4.492

Review 2.  Progress in corticotropin-releasing factor-1 antagonist development.

Authors:  Eric P Zorrilla; George F Koob
Journal:  Drug Discov Today       Date:  2010-03-03       Impact factor: 7.851

3.  Nucleus Accumbens Drd1-Expressing Neurons Control Aggression Self-Administration and Aggression Seeking in Mice.

Authors:  Sam A Golden; Michelle Jin; Conor Heins; Marco Venniro; Michael Michaelides; Yavin Shaham
Journal:  J Neurosci       Date:  2019-01-17       Impact factor: 6.167

Review 4.  Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Authors:  John H Kehne; Christopher K Cain
Journal:  Pharmacol Ther       Date:  2010-09-06       Impact factor: 12.310

5.  Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise.

Authors:  Benjamin N Greenwood; Paul V Strong; Leah Brooks; Monika Fleshner
Journal:  Psychopharmacology (Berl)       Date:  2008-05-03       Impact factor: 4.530

Review 6.  The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology.

Authors:  Elizabeth I Martin; Kerry J Ressler; Elisabeth Binder; Charles B Nemeroff
Journal:  Psychiatr Clin North Am       Date:  2009-09

7.  The effects of the selective 5-HT(2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats.

Authors:  Paul V Strong; Benjamin N Greenwood; Monika Fleshner
Journal:  Psychopharmacology (Berl)       Date:  2008-11-27       Impact factor: 4.530

8.  CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Authors:  T N Douma; M J Millan; D Boulay; G Griebel; P M Verdouw; K G Westphal; B Olivier; L Groenink
Journal:  Psychopharmacology (Berl)       Date:  2013-11-02       Impact factor: 4.530

9.  Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.

Authors:  Adam J Prus; Todd M Hillhouse; Amber L LaCrosse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-23       Impact factor: 5.067

10.  SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats.

Authors:  Darin J Knapp; David H Overstreet; Sheryl S Moy; George R Breese
Journal:  Alcohol       Date:  2004-02       Impact factor: 2.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.